Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: Recent clinically relevant findings from DRCR.net Protocol T

Current Opinion in Ophthalmology

Volumn 28, Issue 6, 2017, Pages 636-643

  Cai, Sophie ^a   Bressler, Neil M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

aflibercept; bevacizumab; diabetic macular oedema; randomized clinical trial; ranibizumab

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DEATH; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DISEASE SEVERITY; DRUG EFFICACY; HEART INFARCTION; HUMAN; INFLAMMATION; INJECTION; INTRAOCULAR PRESSURE ABNORMALITY; LASER COAGULATION; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VISUAL ACUITY; VISUAL ACUITY CHART; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DIABETIC RETINOPATHY; ECONOMICS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; META ANALYSIS; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; COST-BENEFIT ANALYSIS; DIABETIC RETINOPATHY; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 85030751693     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0000000000000424     Document Type: Review

References (43)

1. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond) 2015; 2:17.
2. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early treatment diabetic retinopathy study research group. Arch Ophthalmol 1985; 103:1796-1806.
3. Bressler SB, Glassman AR, Almukhtar T, et al. Five-year outcomes of ranibizumab with prompt or deferred laser versus laser or triamcinolone plus deferred ranibizumab for diabetic macular edema. Am J Ophthalmol 2016; 164:57-68.
4. Chen G, Li W, Tzekov R, et al. Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema: a meta-analysis of randomized controlled trials. PLoS One 2014; 9:e115797.
5. Comyn O, Sivaprasad S, Peto T, et al. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study). Am J Ophthalmol 2014; 157:960-970.
6. Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012; 119:1658-1665.
7. Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology 2016; 123:2376-2385.
8. Ishibashi T, Li X, Koh A, et al. The reveal study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology 2015; 122:1402-1415.
9. Liu XD, Zhou XD, Wang Z, Shen HJ. Comparison of intravitreal bevacizumab with macular photocoagulation for treatment of diabetic macular edema: a systemic review and meta-analysis. Int J Ophthalmol 2014; 7:1048-1055.
10. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012; 130:972-979.
11. Regnier S, Malcolm W, Allen F, et al. Efficacy of anti VEGF and laser photocoagulation in the treatment of visual impairment due to diabeticmacular edema: a systematic review and network meta-analysis. PLoS One 2014; 9:e102309.
12. Barham R, El Rami H, Sun JK, Silva PS. Evidence-based treatment of diabetic macular edema. Semin Ophthalmol 2017; 32:56-66.
13. Klettner A, Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci 2008; 49:4523-4527.
14. Lally DR, Shah CP, Heier JS. Vascular endothelial growth factor and diabetic macular edema. Surv Ophthalmol 2016; 61:759-768.
15. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.NEngl JMed 2015;372:1193-1203.
16. DRCR.net. Modified-ETDRS focal photocoagulation technique. 2013. http:// drcrnet.jaeb.org/ViewPage.aspx?PageName=Investig-Info. [Accessed 12 June 2017]
17. DRCR.net. DRCR.net injection procedure. 2014. http://drcrnet.jaeb.org/ ViewPage.aspx?PageName=Investig-Info. [Accessed 12 June 2017]
18. DRCR.net. Aflibercept, bevacizumab, or ranibizumab forDME: two-year results. 2016. http://drcrnet.jaeb.org/ViewPage.aspx?PageName=Presentations. [Accessed 12 June 2017]
19. Wells JA,Glassman AR, Jampol LM, et al. Association of baseline visual acuity and retinal thickness with 1-year efficacy of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema. JAMAOphthalmol 2016; 134:127-134.
20. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 2016; 123:1351-1359.
21. Tornambe P. Re Wells et al.: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1358). Ophthalmology 2017; 124:e25-e26.
22. Wells JA, Glassman AR, Jampol LM, et al. Reply. Ophthalmology 2017; 124:e26-e27.
23. Jampol LM, Glassman AR, Bressler NM, et al. Antivascular endothelial growth factor comparative effectiveness trial for diabetic macular edema: additional efficacy post hoc analyses of a randomized clinical trial. JAMA Ophthalmol 2016; 134:1429-1434.
24. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86.
25. Thulliez M, Angoulvant D, Le Lez ML, et al. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmol 2014; 132:1317-1326.
26. Virgili G, Parravano M, Menchini F, Evans JR. Antivascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev 2014; CD007419.
27. Zarbin MA, Dunger-Baldauf C, Haskova Z, et al. Vascular safety of ranibizumab in patients with diabetic macular edema: a pooled analysis of patient-level data from randomized clinical trials. JAMA Ophthalmol 2017; 135:424-431.
28. Avery RL, Gordon GM. Systemic safety of prolonged monthly antivascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. JAMA Ophthalmol 2016; 134:21-29.
29. Bressler SB, Liu D, Glassman AR, et al. Change in diabetic retinopathy through 2 years: secondary analysis of a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab. JAMA Ophthalmol 2017; 135:558-568.
30. Ross EL, Hutton DW, Stein JD, et al. Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the Diabetic Retinopathy Clinical Research Network comparative effectiveness trial. JAMA Ophthalmol 2016; 134:888-896.
31. Do DV, Nguyen QD, Vitti R, et al. Intravitreal aflibercept injection in diabetic macular edema patients with and without prior antivascular endothelial growth factor treatment: outcomes from the phase 3 program. Ophthalmology 2016; 123:850-857.
32. Ashraf M, Kayal HE, Souka AAR. Safety and efficacy of ziv-aflibercept in the treatment of refractory diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina 2017; 48:399-405.
33. Ashraf M, Souka AA, ElKayal H. Short-term effects of early switching to ranibizumab or aflibercept in diabetic macular edema cases with nonresponse to bevacizumab. Ophthalmic Surg Lasers Imaging Retina 2017; 48:230-236.
34. Bahrami B, Hong T, Zhu M, et al. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2017; 255:1451-1452.
35. Klein KA, Cleary TS, Reichel E. Effect of intravitreal aflibercept on recalcitrant diabetic macular edema. Int J Retina Vitreous 2017; 3:16.
36. Lim LS, Ng WY, Mathur R, et al. Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab. Clin Ophthalmol 2015; 9:1715-1718.
37. Mira F, Paulo M, Henriques F, Figueira J. Switch to aflibercept in diabetic macular edema patients unresponsive to previous antivegf therapy. J Ophthalmol 2017; 2017:5632634.
38. Rahimy E, Shahlaee A, Khan MA, et al. Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema. Am J Ophthalmol 2016; 164:118-127.
39. Shah CP, Heier JS. Aflibercept for diabetic macular edema in eyes previously treated with ranibizumab and/or bevacizumab may further improve macular thickness. Ophthalmic Surg Lasers Imaging Retina 2016; 47:836-839.
40. Ferris FL 3rd, Maguire MG, Glassman AR, et al. Evaluating effects of switching antivascular endothelial growth factor drugs for age-related macular degeneration and diabetic macular edema. JAMA Ophthalmol 2016; 135:145-149.
41. Blinder KJ, Dugel PU, Chen S, et al. Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (echo study report 1). Clin Ophthalmol 2017; 11:393-401.
42. Elman MJ, Qin H, Aiello LP, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 2012; 119: 2312-2318.
43. Elman MJ, Ayala A, Bressler NM, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 2015; 122:375-381.